FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts

Table 4 PhaseI-II studies of regimens as first and second lines chemotherapy in advanced pancreatic cancer

Regimen	Number of patients	TCR/ORR (%/%)	TTP or PFS (mo)	OS (mo)
Phase I-II studies1
Irinotecan/gemcitabine/5-FU[27]	30	43/7	3.4	8.3
G-FLIP (Irinotecan/gemcitabine/5-FU/cisplatin)[28]	31	68/26	6.1	8.1
FOLFIRI-3 (Irinotecan/5-FU)[20]	40	65/38	5.6	12.1
Irinotecan/S1[29]	16	75/44	4.9	11.3
Phase II studies2
Irinotecan/raltitrexed[32]	19	53/16	4.0	6.5
IROX (Irinotecan/oxaliplatin)[33]	30	33/10	4.1	5.9
IROX (Irinotecan/oxaliplatin)[34]	14	50/21	1.4	4.1
G-FLIP (Irinotecan/gemcitabine/5-FU/cisplatin)[35]	34	44/24	3.9	10.3
Irinotecan/docetaxel[36]	14	21/0	1.2	4.4
MDI (Irinotecan/mitomycin/docetaxel)[37]	15	20/0	1.7	6.1

¹Phases I-II studies of irinotecan and 5-fluorouracil (5-FU)-based regimens as first line chemotherapy;

²Phase II studies of irinotecan-based regimens as second line chemotherapy. TCR: Tumor control rate; ORR: Overall response rate; TTP: Time to progression; PFS: Progression free survival; OS: Overall survival.